%0 Journal Article
%A Dickinson, Michael
%A Cherif, Honar
%A Fenaux, Pierre
%A Mittelman, Moshe
%A Verma, Amit
%A Portella, Maria Socorro O
%A Burgess, Paul
%A Ramos, Pedro Marques
%A Choi, Jeea
%A Platzbecker, Uwe
%A SUPPORT study investigators
%T Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia.
%D 2018
%U https://hdl.handle.net/10668/27323
%X Azacitidine treatment of myelodysplastic syndromes (MDSs) generally exacerbates thrombocytopenia during the first treatment cycles. A Study of Eltrombopag in Myelodysplastic Syndromes Receiving Azacitidine (SUPPORT), a phase 3, randomized, double-blind, placebo-controlled study, investigated the platelet supportive effects of eltrombopag given concomitantly with azacitidine. International Prognostic Scoring System intermediate-1, intermediate-2, or high-risk MDS patients with baseline platelets
%~